Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Scholar Rock to Present at Upcoming Healthcare Conferences

November 2, 2021 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 2, 2021--

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences:

  • Credit Suisse 30 th Annual Virtual Healthcare Conference on Tuesday, November 9 th, 2021 at 8:50 a.m. ET.
  • Cowen 5 th Annual IO Next Virtual Summit on Monday, November 15 th, 2021 at 8:15 a.m. ET.
  • 12 th Annual Jefferies Global Healthcare Conference in London on Wednesday, November 17 th, 2021 at 5:00 p.m. GMT (11:00 a.m. ET).
  • 33 rd Annual Piper Sandler Virtual Healthcare Conference on November 30 th -December 2 nd, 2021. The webcast will be available beginning at 10:00 a.m. ET on November 22.


A live webcast of presentations at the Credit Suisse, Cowen and Jefferies conferences may be accessed by visiting the Investors & Media section of the Scholar Rock website at All these webcasts will be archived and available on the Company’s website for approximately 90 days following the presentation.

About Scholar Rock


Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit or follow Scholar Rock on Twitter ( @ScholarRock ) and LinkedIn ( ).

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

View source version on

CONTACT: Scholar Rock:


Stephanie Ascher

Stern Investor Relations, Inc.


Ariane Lovell

Finn Partners




SOURCE: Scholar Rock

Copyright Business Wire 2021.

PUB: 11/02/2021 04:01 PM/DISC: 11/02/2021 04:02 PM